Just Part of Frank's Story


PixarBio Corporation’s CEO Frank Reynolds to Discuss Non-Opiate/Opioid NeuroRelease on the Pain and Addiction Panel at the 2017 MassBio Annual Meeting in Cambridge, MA on March 31, 2017

Cambridge, Massachusetts (March 30, 2017): PixarBio Corporation (OTC: PXRB) developers of NeuroReleaseTM, announced Founder and CEO Frank Reynolds will be discussing NeuroRelease, PixarBio’s answer to the opiate war at the 2017 MassBio Annual Meeting as a member of the Panel on Pain & Addiction at the Royal Sonesta Boston, Longfellow Room, in Cambridge, MA, at 8:30am on March 31, 2017.

PixarBio Corporation to Attend and Discuss NeuroRelease™ a Morphine Replacement, Non-Opiate, Non Addictive Pain Treatment at the 2017 BIO CEO & Investor Conference in NYC, NY, February 13-14, 2017

Cambridge, Massachusetts (February 13, 2017): PixarBio Corporation (OTC: PXRB) developers of NeuroReleaseTM, a morphine replacement, non-opiate/opioid, non-addictive pain treatment with FDA approval expected in late 2018 for our 14-day post-surgical pain treatment, announced today that it will be attending the BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City, NY, from February 13 – 14, 2017.

PixarBio Corporation Securities Temporarily Suspended From Trading By The Securities and Exchange Commission

Cambridge, Massachusetts (January 27, 2017): PixarBio Corporation (formerly traded on OTCQX as PXRB) announced today that, pursuant to a January 23, 2017 Order, trading of its securities were temporarily suspended by the Securities and Exchange Commission. The suspension is scheduled to last from January 23, 2017 through February 3, 2017 at 11:59 PM. PixarBio is …